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Abstract
Background: Recent research shows that polycystic ovary syndrome (PCOS) may have an association with low-
grade chronic inflammation, and that PCOS may induce an increase in serum interleukin-18 (IL-18) levels.
Methods: To investigate the polymorphisms of the IL-18 gene promoters with PCOS, two single nucleotide
polymorphisms (SNPs) in the promoter of the IL-18 gene (at positions -607C/A and -137G/C) in 118 Chinese
women with PCOS and 79 controls were evaluated using polymerase chain reaction (PCR).
Results: No significant differences were found in the genotype distribution, allele frequency and haplotype
frequency between the PCOS and control groups. Further analysis demonstrated a relationship between IL-18 gene
promoter polymorphisms and PCOS insulin resistance (IR). Regarding the -137 allele frequency, G and C allele
frequencies were 93.5% and 6.5%, respectively, in the PCOS with IR patients; G and C allele frequencies were 85.4%
and 14.6%, respectively, in PCOS patients without IR (chi2 = 3.601, P = 0.048).
Conclusions: The presence of a polymorphism in the IL-18 gene was found to have no correlation with the
occurrence of PCOS. Carriage of the C allele at position -137 in the promoter of the IL-18 gene may play a
protective role from the development of PCOS IR.
Background
Polycystic ovary syndrome (PCOS) is a common and
complex endocrine disorder of women in their repro-
ductive years, with prevalence between 5% and 10% of
the general population [1,2]. The etiology of PCOS
remains controversial, but there is evidence suggesting
that genetic factors may play an important role [3,4].
Studies have shown that a common polymorphism of
the interleukin-1a gene (IL) is associated with the pre-
sence of PCOS [5], and a polymorphism of the IL-6 pro-
moter is associated with clinical characteristics of
women affected by PCOS [6].
T h r e es i n g l en u c l e o t i d ep o l y m o r p h i s m s( S N P s )i nt h e
promoter of the IL-18 gene at positions -656G/T,
-607C/A and -137G/C have been identified; the two
SNPs at positions -607C/A and -137G/C are predicted
to influence the expression of IL-18 and, potentially,
interferon -g (IFN)[7].
In order to investigate the possible roles of IL-18 in the
pathogenesis of PCOS and its relationship with insulin
resistance (IR), obesity and hyperandrogenism, the poly-
morphisms at positions -607 and -137 in the promoter of
the IL-18 gene in PCOS patients has been investigated.
Methods
Patients and control groups
A total of 118 patients with PCOS were included in this
prospective, case-controlled study. Mean age at diagnosis
was 28.60 years (S.D. = 3.45). For this study, data from
women with PCOS visiting the Department of Obstetrics
and Gynecology, Division of Reproductive Center, Peking
University Third Hospital, Beijing, from October 2006 to
January 2007 were analyzed. All patients were Chinese
and had not taken medications, including contraceptive
pills, for the last 6 months. None of the patients had any
clinical evidence (history or examination) of a recent or
ongoing infection. Women having received any hormonal
* Correspondence: jie.qiao@263.net
Department of Obstetrics and Gynecology, Peking University Third Hospital,
Beijing, P.R China
Yang et al. Reproductive Biology and Endocrinology 2010, 8:125
http://www.rbej.com/content/8/1/125
© 2010 Yang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.treatment or insulin-lowering agent during the last
3 months were excluded from the study. Institutional
Review Board approval was obtained for this study and
patients’ consent was obtained from all women prior to
inclusion in the study.
The diagnosis of PCOS was based on the 2003 Rotter-
dam ESHRE/ASRM criteria: (1) oligoovulation(cycle
intervals > 35 days) and/or anovulation (absence of
menstruation for 3 consecutive months); (2) clinical
and/or biochemical signs of hyperandrogenism (patients
presented with hirsute (Ferriman-Gallwey scale ≥ 6),
acne or alopecia, and/or increased circulating levels of
testosterone, T ≥ 2.8 nmol/L); (3) polycystic ovaries(12
or more follicles 2-9 mm in diameter and/or increased
ovarian volume of more than 10 mL). All other aetiolo-
gies (congenital adrenal hyperplasia, androgen-secreting
tumors, Cushing’s syndrome) were excluded [8].
The control group consisted of 79 subjects with a
mean age of 29.82 years (S.D. = 3.86). Controls were
recruited by word of mouth and hospital advertisements
calling for “healthy women”. All controls underwent a
brief history, physical exam and chemical examination
of serum hormones, ensuring that all control women
were non-hirsute and had regular menstrual cycles, nor-
mal androgen levels and had birthed at least one child.
For further analysis the PCOS patients were divided into
two sub-groups three times. Firstly, PCOS IR group and
PCOS without IR group, insulin resistance was judged by
using the homeostatic model IR index (HOMA-IR), and
2.69 was selected as a cutoff point [9,10]. Secondly, the
PCOS patients were divided into obese PCOS patients and
lean PCOS patients, BMI < 25 kg/m
2 had been used as a
cutoff point. Finally, PCOS with hyperandrogenism group
and PCOS without hyperandrogenism: group, we assessed
total testosterone, 2.8 nmol/L was used as a cutoff point.
Blood and tissue DNA isolation
All subjects underwent a brief physical examination,
including: height, weight, body mass index [BMI was
calculated as follows: weight (kilograms)/height
2
(meters)] and blood sampling for hormonal measure-
ment. Blood samples were obtained between days 2 and
3 of the menstrual cycle. In patients with amenorrhea,
bleeding was induced by progestogens, with blood sam-
ples taken thereafter. If no bleeding occurred, blood
samples were taken after validating the lack of an estab-
lished pregnancy by a commercially available pregnancy
test. Blood was taken from the antecubital vein after
12-hours of overnight fasting. Samples were immediately
centrifuged, with the serum separated and frozen at
-20°C until assayed.
Fasting insulin (FIN), follicle- stimulating hormone
(FSH), luteinizing hormone (LH) and total testosterone
(T) levels were determined by chemiluminescence-
immunoassay (CLIA) and fasting glucose (FBG) levels
were detected using the glucose oxidase method.
DNA was extracted from EDTA- collected peripheral
whole blood with standard techniques following the
manufacturer’s instructions and stored at -20°C.
Fasting glucose and insulin values were also obtained
for each of the subjects. The homeostasis model assess-
ment (HOMA) was used to calculate indices of insulin
resistance and insulin secretion for each patient [11].
Homeostasis model assessment index for IR (HOMA-
IR) was calculated as follows: fasting insulin (mIU/l) ×
fasting glucose (mmol/L)/22.5.
Polymerase chain reaction
Polymorphisms were analyzed by using PCR-SSP, at posi-
tions -607 and -137 in the promoter of the IL-18 gene
[7]. For the position -607C/A- specific PCR, a common
reverse primer 5’-TAACCTCATTCAGGACTTCC-3’
and two sequence-specific forward primers 5’-GTTGCA-
GAAAGTGTAAAAATTATTA C-3’ and 5’-GTTGCA-
GAAAGTGTAAAAATTATTAA-3’ were used. An
amplification product of 196 bp was detected. A control
forward primer 5’-CTTTGC TATCATTCCAGGAA-3’
was used to amplify a 301 bp fragment covering the poly-
morphic site as an internal positive amplification control.
PCR reaction was performed in a final volume of 25 μL
consisting of 2.5 μL 10 × PCR buffer, 0.5 μLd N T P ,
1.5 μLg e n o m i cD N Aa n d0 . 5μLT a qp o l y m e r a s e .O n e
sequence-specific primer (for the C allele or A allele), the
common reverse primer, and the internal position con-
trol primer were included in every reaction mixture at a
concentration of 0.25 μL, respectively. Therefore, two
PCR reactions were performed for every individual DNA.
Reactions were carried out in a Gene Amp PCR Sys-
tem 9600 (Perkin Elmer, USA) thermal cycler. Dena-
turation was performed for 2 min at 94°C, followed by
30 cycles at 94°C for 30 s, 57°C for 30 s, 72°C for 30 s
and 72°C for 5 min. PCR products were visualized by
3% agarose gel electrophoresis. The molecular weight of
PCR products was estimated using a 100-bp DNA lad-
der (Roche, Germany). PCR products were visualized
and photographed under UV with an Alpha Imager
1220 v 5.5 Camera software
For the -137 genotyping, a common reverse primer 5’-
AGGAGGGCAAAATGC ACTGG-3’ and two sequence-
specific forward primers 5’-CCCCAACTTTTACGG
AAGAAAAG-3’ and 5’-CCCCAACTTTTACGGAA-
GAAAAC-3’ were used. An amplification product of 261
bp was detected. A control forward primer 5’-CCAATA
GGACTGATTATTCCGCA-3’ was used to amplify a 446
bp fragment covering the polymorphic site to serve as an
internal positive amplification control. PCR reaction was
performed in a final volume of 25 μL consisting of 2.5 μL
10 × PCR buffer, 0.5 μL dNTP, 1.5 μL genomic DNA and
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mer, the reverse primer, and sequence-specific primers
was 0.25 μL, respectively. The PCR was run as follows:
denaturation for 2 min at 94°C, followed by 30 cycles
of 94°C for 30 s, 57°C for 30 s, 72°C for 30 s and 72°C for
5 min.
Statistical analysis
T h ep r i m a r yp h e n o t y p ef o rg e n e t i ca s s o c i a t i o na n a l y s i s
was the presence or absence of PCOS, given that such
analysis utilizes all available subjects to maximize power.
Secondary analyses included the insulin-related traits
(fasting insulin, fasting glucose, HOMA-IR), adiposityre-
lated traits (BMI) and androgen-related traits (T), within
PCOS.
The frequencies of genotypes and alleles in the pro-
moter region of the IL-18 gene at positions -607 and
-137 were calculated by counting. Data were analyzed
with SPSS statistical software system (SPSS 11.5; SPSS
Inc., Chicago, IL) and the Hardy-Weinberg equilibrium
was determined by means of chi square testing. Statisti-
cal significance was assumed for P values less than 0.05.
Results
IL18 gene polymorphism
Polymorphisms at positions -607 and -137 in the pro-
moter of the IL-18 gene were analyzed by PCR-SSP. At
every polymorphic site, a common reverse primer and
two sequence-specific forward primers were used,
resulting in two PCR reactions performed for every indi-
vidual DNA. The specific PCR products from homozy-
gous individuals showed one DNA segment, while
heterozygous individuals exhibited two specific frag-
ments, as expected. In total, 197 unrelated Chinese sub-
jects were studied for IL-18 promoter polymorphisms.
As shown in Figure 1, there were CC, CA and AA geno-
types at position -607, and GG, GC and CC genotypes
at position -137.
Comparison of IL18 gene polymorphism between PCOS
patients and controls
Genotype and allele frequencies for IL-18 polymorph-
isms are summarized in Table 1. The genotype frequen-
cies were in agreement with the Hardy-Weinberg
equilibrium (P > 0.1 for all analyses). For the -607 geno-
types from the 118 PCOS patients, 39 had the CC type
(33%), 61 the CA type (51.7%), and 18 the AA (15.3%).
Of the 79 control subjects, 22 had the CC type (27.8%),
48 the CA type (60.8%), and 9 the AA type (11.4%).
Regarding the -137 genotypes, 92 of the 118 PCOS
patients had the GG type (78.0%), 25 the GC type
(21.2%), and 1 the CC type (0.8%). Sixty-three of the 79
control subjects were type GG (79.7%) and 16 were GC
(20.3%). No significant differences were observed in the
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Figure 1 Genotyping for the IL-18 position -137 and -607
polymorphisms. M: DL600 DNA Marker; lanes 1-3: -137 GG, GC and
CC; lanes 4-6: -607 CC, CA and AA.
Table 1 Comparison of IL18 gene promoter
polymorphism between PCOS patients and controls
PCOS N = 118
(%)
controls n = 79
(%)
c
2 P
Position -607
genotype
CC 39(33.0) 22(27.8) 1.631 0.442
CA 61(51.7) 48(60.8)
AA 18(15.3) 9(11.4)
Alleles
C 139(58.9) 92(58.2) 0.018 0.895
A 97(41.1) 66(41.8)
Position -137
genotype
GG 92(78.0) 63(79.7) 0.708 0.702
GC 25(21.2) 16(20.3)
CC 1(0.8) 0
Alleles
G 209(88.6) 142(89.9) 0.168 0.682
C 27(11.4) 16(11.1)
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PCOS and control groups.
Based on genotypes of the IL-18 promoter polymorph-
isms, haplotype frequencies were estimated by the
expectation maximization method. Four haplotypes of
the IL-18 promoter at positions -607 and -137 were pre-
sent in both patients and controls (haplotypes I, II, III
and IV in Table 2). The frequencies of haplotypes I, II,
III and IV in the PCOS patients were 57.0%, 0.6%,
30.7% and 11.7%, respectively. The frequencies of haplo-
types I, II, III and IV in the controls were 28.2%, 0%,
31.6% and 10.2%, respectively. No significant differences
were observed in the haplotype frequencies between the
PCOS and the controls.
Comparison of IL18 gene polymorphism between PCOS
patients with IRand without IR
For further analysis of the relationship between IL-18 gene
promoter polymorphisms and PCOS IR. Insulin resistance
was judged by using the homeostatic model IR index
(HOMA-IR), and 2.69 was selected as a cutoff point [9,10].
T h eP C O Sp a t i e n t sw e r ed i v i d e di n t ot w os u b - g r o u p s :
PCOS IR: HOMA-IR ≥ 2.69; PCOS without IR: HOMA-IR
< 2.69. Genotype and allele frequencies for IL-18 poly-
morphisms are summarized in Table 3. There were no sig-
nificant differences in the genotype frequencies between
the two sub-groups. As for the -137 allele frequencies, G
allele frequency was 93.5% and C allele frequency was
6.5% in the PCOS IR group. In the PCOS without IR
group, the G allele frequency was 85.4% and C allele fre-
quency was 14.6%. There was indeed a significant differ-
ence in the allele frequency between the two sub-groups
(P = 0.048). Four haplotypes of the IL-18 promoter at
positions -607 and -137 were present in the two sub-
groups; they are summarized in Table 4. There were no
significant differences in the haplotype frequencies
between the PCOS IR and PCOS without IR groups.
Comparison of IL18 gene polymorphism between obese
and lean PCOS women
For further analysis of the relationship between the
IL-18 gene promoter polymorphisms and PCOS IR, the
PCOS patients were again divided into two sub-groups:
obese PCOS: BMI ≥ 25 kg/m
2;l e a nP C O S :B M I<2 5
kg/m
2. Genotype and allele frequencies for IL-18 poly-
morphisms are summarized in Table 5; four haplotypes
of the IL-18 promoter at positions -607 and -137 were
present in the two sub-groups, which are summarized in
Table 6. There were no significant differences in the
genotype distribution, allele frequencies, or haplotype
frequencies between obese and lean PCOS women.
Comparison of IL18 gene polymorphism between PCOS
patients with and without hyperandrogenism
For further analysis of the relationship between the
IL-18 gene promoter polymorphisms and PCOS IR, the
PCOS patients were again divided into two sub-groups:
PCOS with hyperandrogenism: T ≥ 2.8 nmol/L; PCOS
without hyperandrogenism: T < 2.8 nmol/L. Genotype
and allele frequencies for IL-18 polymorphisms are sum-
marized in Table 7; four haplotypes of the IL-18 promo-
ter at positions -607 and -137 were present in the two
sub-groups, and are summarized in Table 8. There were
no significant differences in the genotype distribution,
allele frequencies, or haplotype frequencies between
PCOS subjects with and without hyperandrogenism.
Discussion
IL-18 is a proinflammatory cytokine that induces the
production of TNF-a [12], IL-6 [13], and C-Reactive
Protein (CRP) [14]. Like IL-6 and CRP, IL-18 is con-
sidered a strong risk marker for cardiovascular death
[15]. Women with PCOS have chronic low-level
inflammation [16,17], often associated with obesity and
a subsequent increased risk for type 2 diabetes [18-20].
Recently, study has shown that PCOS induces an
Table 2 Haplotype frequencies of two interleukin-18
bi-allellic polymorphisms in PCOS and controls
Haplotype -607C/
A
-137G/
C
PCOS n
(%)
controls n
(%)
c
2 P
I C G 135(57.0) 92(58.2) 0.058 0.81
II C C 1(0.6) 0(0) 0.406 0.52
III A G 72(30.7) 50(31.6) 0.039 0.84
IV A C 28(11.7) 16(10.2) 0.228 0.63
Total 236 158
Table 3 Comparison of IL18 gene promoter
polymorphism between PCOS patients with IR and
without IR
PCOS IR
n = 46 (%)
PCOS without
IR n=72 (%)
c
2 P
Position -607 genotype
CC 19(41.3) 20(27.7) 2.328 0.312
CA 21(45.7) 40(55.6)
AA 6(13.0) 12(16.7)
Alleles
C 59(64.1) 80(55.6) 1.705 0.192
A 33(35.9) 64(44.4)
Position -137 genotype
GG 40(87.0) 52(72.2) 3.780 0.151
GC 6(13.0) 19(26.4)
CC 0(0) 1(1.4)
Alleles
G 86(93.5) 123(85.4) 3.601 0.048
C 6(6.5) 21(14.6)
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ciated with several indexes of global and visceral adip-
osity, and with insulin IR [21]. It has been suggested
that IL-18 may be a contributing factor linking inflam-
mation and IR in PCOS women [22].
The human IL-18 gene is located on chromosome
11q22.2-q22.3; it is composed of six exons and five
introns [23]. Kruse et al. [24] and Sugiura et al. [25]
described three SNPs at positions -656G/T, -607C/A
and -137G/C in the promoter of the first exon of the
IL-18 gene. A change from C to A at position -607 dis-
rupts a potential cAMP-responsive element-binding pro-
tein binding site; a change at position -137 from G to C
changes the H4TF-1 nuclear factor binding site. Cloning
and gene expression analysis demonstrated that two
SNPs of the IL-18 promoter at positions -607 and -137
were suggested to cause the differences in transcription
factor binding. They may also have an impact on IL-18
gene activity and also to interferon-g (IFN). Potentially,
the G/C polymorphisms at position -137 could play a
major role in the expression of IL-18.
These promoter SNPs have also been implicated as
susceptibility loci for various diseases, including type 1
diabetes [25,26], rheumatoid arthritis [27,28], sarcoidosis
[29], atopic eczema [30], adult-onset Still’s disease [24],
and seasonal allergic rhinitis [23]. Kretowski et al. [25]
genotyped 201 case and 194 unrelated control subjects
from Poland, reporting that the C allele at -137 (G-C)
was associated with type 1 diabetes (odds ratio [OR] 1.6;
P = 0.002). At -607, case subjects reported an increase
in the proportion of the C/A genotype relative to con-
trol subjects (64.2% case and 56.7% control subjects),
while a decrease was seen in the proportion of the A/A
genotype in case subjects (0% case and 5.7% control
subjects).
In the present study, two polymorphisms in the pro-
moter regions of the IL-18 gene were identified. The
association between these polymorphisms and PCOS
were demonstrated. The results showed no significant
differences in the distribution of genotypes, allelic or
haplotype frequencies for polymorphisms of the IL-18
gene between PCOS patients and control subjects. IL-18
gene polymorphisms had no direct relationship with the
pathogenesis of PCOS.
Further analysis of the relationship between IL-18
gene promoter polymorphisms and the existence of
PCOS IR showed that C allele frequency at position
-137 in the IL-18 gene promoter was closely associated
with PCOS IR (chi2 = 3.601, P = 0.048 < 0.05). Carriage
of the C allele at position -137 in the promoter of the
IL-18 gene may play a protective role from the develop-
ment of PCOS IR.
The relationship between IL-18 gene promoter poly-
morphism and PCOS obesity and hyperandrogenism
were also studied; the results showed that the distribu-
tion of genotypes, allelic or haplotype frequencies for
polymorphisms of the IL-18 gene, have no differences.
It illustrated that the role of IL-18 gene promoter poly-
morphism had no relationship with obesity and hyper-
androgenism of PCOS patients.
This was the first research exploring the role of IL-18
gene promoter polymorphism in the etiology of PCOS
and its relation with IR and obesity.But we study only
two site of IL-18 gene polymorphism, we will continue
our work in the future. Moreover, the samples of this
study was not large enough, the real roles of IL-18 in
the pathogenesis of developing PCOS should be further
investigated by large population-based studies.
Table 4 Haplotype frequencies of two interleukin-18 bi-allelic polymorphisms in PCOS patients with IR and without IR
Haplotype -607C/A -137G/C PCOS IR n (%) PCOS without IR n (%) c
2 P
I C G 59(64.1) 79(54.7) 2.035 0.15
II C C 0(0) 3(2.2) 1.293 0.26
III A G 27(29.4) 45(31.4) 0.108 0.74
IV A C 6(6.5) 17(11.7) 1.72 0.19
Total 92 144
Table 5 Comparison of IL18 gene promoter
polymorphism between obese PCOS women and lean
PCOS women
Obese PCOS
n=54(%)
Lean PCOS
n=64(%)
c
2 P
Position -607
genotype
CC 9(14.0) 9(16.7) 0.510 0.775
CA 26(54.7) 35(48.1)
AA 19(31.3) 20(35.2)
Alleles
C 44(40.7) 53(41.4) 0.011 0.918
A 64(59.3) 75(58.6)
Position -137
genotype
GG 42(77.7) 50(78.1) 1.217 0.544
GC 11(20.4) 14(21.9)
CC 1(1.9) 0
Alleles
G 95(88.0) 114(89.1) 0.070 0.791
C 13(12.0) 14(10.9)
Yang et al. Reproductive Biology and Endocrinology 2010, 8:125
http://www.rbej.com/content/8/1/125
Page 5 of 7Conclusions
In summary, IL-18 gene polymorphisms had no direct
relationship with the pathogenesis of PCOS. Our results
suggest that carriage of the C allele at position -137 in
the promoter of the IL-18 gene may play a protective
role from the development of PCOS IR.
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